- Home
- BMEA vs RDIB Comparison
BMEA vs RDIB Comparison
Compare BMEA & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- RDIB
- Stock Information
- Founded
- BMEA 2017
- RDIB 1937
- Country
- BMEA United States
- RDIB United States
- Employees
- BMEA N/A
- RDIB N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- RDIB Movies/Entertainment
- Sector
- BMEA Health Care
- RDIB Consumer Discretionary
- Exchange
- BMEA Nasdaq
- RDIB Nasdaq
- Market Cap
- BMEA 145.0M
- RDIB 140.2M
- IPO Year
- BMEA 2021
- RDIB N/A
- Fundamental
- Price
- BMEA $3.46
- RDIB $6.86
- Analyst Decision
- BMEA Buy
- RDIB
- Analyst Count
- BMEA 13
- RDIB 0
- Target Price
- BMEA $27.92
- RDIB N/A
- AVG Volume (30 Days)
- BMEA 414.8K
- RDIB 859.0
- Earning Date
- BMEA 03-31-2025
- RDIB 03-28-2025
- Dividend Yield
- BMEA N/A
- RDIB N/A
- EPS Growth
- BMEA N/A
- RDIB N/A
- EPS
- BMEA N/A
- RDIB N/A
- Revenue
- BMEA N/A
- RDIB $197,270,000.00
- Revenue This Year
- BMEA N/A
- RDIB N/A
- Revenue Next Year
- BMEA N/A
- RDIB $18.29
- P/E Ratio
- BMEA N/A
- RDIB N/A
- Revenue Growth
- BMEA N/A
- RDIB N/A
- 52 Week Low
- BMEA $3.25
- RDIB $5.78
- 52 Week High
- BMEA $19.36
- RDIB $21.34
- Technical
- Relative Strength Index (RSI)
- BMEA 34.96
- RDIB 50.90
- Support Level
- BMEA $3.25
- RDIB $6.83
- Resistance Level
- BMEA $3.75
- RDIB $7.48
- Average True Range (ATR)
- BMEA 0.24
- RDIB 0.22
- MACD
- BMEA 0.00
- RDIB 0.09
- Stochastic Oscillator
- BMEA 21.43
- RDIB 58.90
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.